MAP2K2 (phospho-Thr394) Antibody
- Known as:
- MAP2K2 (phosphorilated-Thr394) Antibody
- Catalog number:
- abx000173
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- MAP2K2 (phospho-Thr394) Antibody
Related genes to: MAP2K2 (phospho-Thr394) Antibody
- Gene:
- MAP2K2 NIH gene
- Name:
- mitogen-activated protein kinase kinase 2
- Previous symbol:
- PRKMK2
- Synonyms:
- MEK2
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-05
- Date modifiied:
- 2019-04-23
Related products to: MAP2K2 (phospho-Thr394) Antibody
Related articles to: MAP2K2 (phospho-Thr394) Antibody
- Melanoma is a highly aggressive cancer in both humans and dogs with significant biological and clinical similarities. This study aimed to identify therapeutic kinase targets in canine melanoma by screening kinase inhibitors in canine melanoma cell lines. Cell viability assays showed that seven inhibitors reduced viability in both CMGD2 and TLM1 cells, whereas additional compounds showed cell line-specific activity. The most promising kinase targets were AURKA, AURKB, AXL, CLK1/2/4, IGF1R, MAP2K1, and MAP2K2. Gene expression analysis confirmed expression of these targets in the cell lines, except for CLK3. In silico analyses revealed high structural homology (≥90%) between canine and human kinases, supporting the translational relevance of these findings. Molecular docking further demonstrated similar predicted binding profiles between human and canine kinases. Several FDA-approved drugs targeting these kinases were identified as potential repurposing candidates for canine melanoma treatment. These findings highlight the potential of targeted therapies for canine melanoma and reinforce the value of comparative oncology in advancing precision medicine across species. However, these findings are based on an exploratory single-dose in vitro screen, a small tumor cohort, and in silico analyses, and therefore require dose-response, protein-level, and in vivo validation. - Source: PubMed
Publication date: 2026/05/07
Andriotti Lucas AntonioXavier Pedro Luiz PorfírioRochetti Arina LázaroQazi Talal JamilFerrero Aline Takahashide Francisco Strefezzi RicardoGomes Cristina Oliveira Massoco SalesDagli Maria Lucia ZaidanLeitão AndreiDa Silva Edson RobertoMuller SusanneFukumasu Heidge - Melanoma is an aggressive malignancy with a high propensity for metastasis, and approximately 3% of cases present as melanoma of unknown primary (MUP), posing diagnostic and management challenges. We report a 63-year-old man who presented with painful, rapidly enlarging axillary and cervical lymphadenopathy without an identifiable cutaneous lesion. Fine-needle aspiration (FNA) of an axillary lymph node revealed a hypercellular specimen composed of highly pleomorphic malignant cells with prominent nucleoli and abundant cytoplasm. Immunocytochemistry demonstrated diffuse nuclear SOX10 expression and focal Melan-A positivity, with negative pancytokeratin staining, supporting a diagnosis of melanoma. Subsequent excisional biopsy confirmed metastatic melanoma with concordant SOX10 and S100 immunoreactivity. Comprehensive genomic profiling detected genomic alterations, including BRAF (K601E), MAP2K2 (E207K), TP53 (W146*) and a TERT promoter -146C>T mutation, along with CDKN2A/B loss and MYC amplification; no KIT or NRAS mutations were detected. Tumour mutational burden (TMB) was 18 mutations/Mb, and the tumour was microsatellite stable. This case highlights the clinical utility of a cytology-first diagnostic workflow for MUP, in which FNA combined with a targeted immunohistochemical panel enables rapid lineage confirmation and facilitates timely surgical excision and molecular testing. Integration of cytologic diagnosis with genomic analysis provides a practical, real-world approach to precision oncology in complex metastatic presentations of melanoma. - Source: PubMed
Publication date: 2026/04/27
Yu HongAbdelhammed MokhtarCao XuRamani Nisha S - Stem cell-derived insulin-producing cells (Ins-PCs) hold great promise for diabetes treatment. Placenta-derived multipotent stem cells (PMSCs) are considered an ideal source of Ins-PC generation due to their immunomodulatory and differentiation properties. However, the cellular and molecular pathways underlying PMSC differentiation to Ins-PCs have not been fully elucidated. In this study, PMSCs were isolated from human placenta and successfully differentiated into Ins-PCs using miRNA-181a mimics. Differentiated Ins-PCs produced a significant amount of insulin and upregulation of C-peptide, insulin, and MAFA expression, compared to undifferentiated control PMSCs. RNA sequencing and LC-MS/MS were performed to uncover the pathways involved in the Ins-PC differentiation process. RNA sequencing revealed the transcriptional landscape of PMSC-derived Ins-PC differentiation. Pathway analysis identified important pathways involved in the differentiation process, including Notch and Wnt/ß-catenin, and so forth. Proteomics analysis further affirmed the presence of key insulin pathway-related proteins involved in the differentiation of PMSCs into Ins-PCs, including LEPR, STC2, MAP2K2, and so forth. Moreover, integrated transcriptomic and proteomic analyses further highlighted LEPR as a potential key regulator for Ins-PC differentiation. These findings demonstrated the feasibility of generating Ins-PCs from PMSCs and identified potential signaling pathways and regulators underlying Ins-PC differentiation, supporting PMSCs as a promising stem cell source of cell-based therapy for diabetes treatment. - Source: PubMed
Publication date: 2026/04/01
Xu JieShen XingguiGu YangLewis David FZoorob DaniWang Yuping - Cardiofaciocutaneous syndrome type 4 (CFC4) is a rare genetic condition caused by pathogenic variants in the MAP2K2 (MEK2) gene, part of the RAS/MAPK signaling pathway. While the broader phenotype of CFC syndrome has been well described, the features specific to this molecular subtype remain poorly defined due to the limited number of cases and underreporting. We conducted a structured analysis of all available literature on CFC4, focusing on organ-specific manifestations, including cardiac, craniofacial, neurological, integumentary, and gastrointestinal features, as well as developmental outcomes, treatment approaches, imaging findings, and behavioral profiles. Cardiofaciocutaneous syndrome type 4 is associated with a recognizable but variable phenotype. Pulmonary valve stenosis and atrial septal defects (ASDs) are the most common cardiac anomalies. Neurological involvement is nearly universal, often presenting as hypotonia and motor delay, with intellectual disability in a subset of cases. Distinctive craniofacial features and ectodermal abnormalities support clinical recognition. Feeding difficulties, sensory integration disorders, and behavioral challenges are frequently observed. Brain magnetic resonance imaging (MRI) abnormalities such as ventriculomegaly and corpus callosum hypoplasia are also relatively frequent. Notably, some individuals with CFC4 exhibit relatively mild phenotypes, with reports of independent functioning in adulthood and a history of familial transmission. In such cases, only mild learning difficulties were described. Better recognition and understanding of CFC4 require consistent and detailed reporting of new cases. To support this, we propose a concise clinical checklist to standardize case descriptions and support diagnosis. - Source: PubMed
Publication date: 2026/03/30
Kubiszewski HubertŚwieca AleksandraŁukasiewicz KacperPierpont Elizabeth IreneSzczałuba Krzysztof - The hypothesis-generating case study aimed at identifying those who are sensitive to anti-PD-L1 and TGF-β bifunctional fusion proteins and exploring potential mechanisms in the treatment of recurrent cervical cancer. We report that recurrent cervical cancer treated with anti-PD-L1 and TGF-β bifunctional fusion proteins in Qilu Hospital of Shandong University show distinct clinical therapeutic outcomes. We describe the clinical course, characteristics, and genetic characteristics of the patients and analyzed the differentially expressed genes (DEGs) following treatment. The elevation of peripheral blood lymphocytes after treatment may predict response to anti-PD-L1 and TGF-β bifunctional fusion proteins, since partial response (PR) and progressive disease (PD) exhibit different trends. A total of 4,844 DEGs were selected between PR and PD patients during the anti-PD-L1 and TGF-β bifunctional fusion protein treatments, which are believed to be involved in the regulation of the immune response. We demonstrated that changing-fate genes continuously change during treatment fostering the IL 17 signaling pathway and TGF-β signaling pathways. Finally, we identified the prognostic genes and validated that high expression levels of PMEPA1, FSTL3, SERPINE1, CXCL1, CXCL8, and low expression levels of JUND，MAP2K2 were significantly associated with poor prognosis of cervical cancer patients using the TCGA database. Anti-PD-L1 and TGF-β bifunctional fusion proteins are feasible and effective for recurrent cervical cancer through the IL 17 signaling pathway and TGF-β signaling pathways. A novel immune infiltration-based gene signature consisting of PMEPA1, FSTL3, SERPINE1, CXCL1, CXCL8, JUND, and MAP2K2 plays a crucial role in recurrent cervical cancer patients with anti-PD-L1 and TGF-β bifunctional fusion proteins. - Source: PubMed
Publication date: 2026/03/23
Mao YucenXing NaidongSun WenxiongBao XinyueLiu XihanWu RichaoPeng Jin